Linkedin

News and events

  • All
  • Events
  • Press releases
  • Publications
All
  • All
  • Events
  • Press releases
  • Publications

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir, which is developing single domain antibody therapies providing broad
September 1, 2021
Read More

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad
August 18, 2021
Read More

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir, which is developing single domain antibody therapies providing broad
July 15, 2021
Read More

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir, which is developing single domain antibody therapies providing broad
July 13, 2021
Read More

ExeVir Announces Close of $50 million/ EUR42 million Series A Financing

ExeVir, which is developing single domain antibody therapies providing broad
March 16, 2021
Read More